SNDXHealthcare · BiotechnologyThe 12 Wall Street analysts covering Syndax Pharmaceuticals, Inc. hold a median 12-month price target of $37 — +172.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 22 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Syndax Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SNDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +172.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $38 |
| 21 Aug 2026 | UBS | Maintains | Buy | $37 → $33 |
| 21 Aug 2026 | UBS | Maintains | Buy | — |
| 11 Aug 2026 | JP Morgan | Maintains | Overweight | $44 → $40 |
| 11 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $38 |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $40 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $40 |
| 12 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2026 | UBS | Maintains | Buy | — |
| 1 May 2026 | Barclays | Maintains | Overweight | — |
| 1 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 31 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 30 Mar 2026 | Jefferies | Assumes | Buy | $48 → $40 |
| 9 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 2 Mar 2026 | Citigroup | Maintains | Buy | — |
| 27 Jan 2026 | Mizuho | Maintains | Outperform | $410 → $600 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SNDX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Syndax Pharmaceuticals, Inc. returned −10.2% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 25% of US stocks
Cheaper than 2% of US stocks
Cheaper than 82% of US stocks
Higher than 92% of US stocks
Higher than 82% of US stocks
Higher than 98% of US stocks
Higher than 16% of US stocks
Higher than 7% of US stocks
Higher than 6% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Syndax Pharmaceuticals, Inc. has a market value of $1.2B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $252.3M. The latest quarter grew 91.8% year on year.
Net income over the same four quarters: −$220.8M, a −87.5% net margin.
Diluted earnings per share, trailing twelve months: $−2.51.
Free cash flow in the twelve months to 30 June 2026: −$220.9M.
Trailing P/E: −4.1×; forward P/E: −15.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Syndax Pharmaceuticals, Inc. employs 298 people — $846K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Syndax Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SBS Law announced an opportunity for Syndax Pharmaceuticals investors with $100,000 in losses to join a fraud investigation.
Why it matters — The announcement concerns a fraud investigation involving Syndax Pharmaceuticals and may be relevant to SNDX investors monitoring legal matters.
Syndax Pharmaceuticals announced that TIME selected Revuforj® (revumenib), its first-in-class menin inhibitor, for its 2026 Best Inventions list in the Medical and Healthcare category.
Why it matters — The recognition highlights a Syndax cancer therapy in TIME’s annual list of 300 inventions.
Syndax shares fell 16% after its Phase II axatilimab study missed the primary endpoint. The company will abandon development of axatilimab for idiopathic pulmonary fibrosis.
Why it matters — The study result and decision to stop development affect SNDX’s idiopathic pulmonary fibrosis program.
Syndax’s Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint. SueWallSt announced a pending investigation into potential securities law violations on behalf of investors who lost money.
Why it matters — The trial result was associated with SNDX shares opening down more than 11%, and the notice reports a pending investor-focused investigation.
Syndax Pharmaceuticals will halt clinical development of axatilimab in idiopathic pulmonary fibrosis after it missed the primary endpoint in the Phase 2 MAXPIRe trial.
Why it matters — The decision marks a setback for SNDX’s axatilimab program in IPF.
The 12 Wall Street analysts covering Syndax Pharmaceuticals, Inc. have a median 12-month price target of $37, with estimates ranging from $23 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Syndax Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Syndax Pharmaceuticals, Inc. 58 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Syndax Pharmaceuticals, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +172.7% from the last close, and Ticker Nerd's factor model ranks Syndax Pharmaceuticals, Inc. 58 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Syndax Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $57 over the next 12 months.
Syndax Pharmaceuticals, Inc. returned -10.2% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies.
The most recent item we track (Business Wire, 18 Oct 2026): "SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law". SBS Law announced an opportunity for Syndax Pharmaceuticals investors with $100,000 in losses to join a fraud investigation.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease. The company’s work spans research, regulatory advancement, and commercial execution, combining clinical development with product launch and market support. Syndax Pharmaceuticals also collaborates with partners to broaden access to its therapies and strengthen its presence in oncology and related specialty care markets. Headquartered in New York, New York, Syndax Pharmaceuticals, Inc. plays a role in advancing targeted treatment options for patients with high unmet medical needs.
CEO Mr. Michael A. Metzger M.B.A. · 298 employees · United States · https://syndax.com
